Zoetis Inc. (FRA:ZOE)
Germany · Delayed Price · Currency is EUR | Market Cap | 27.50B -57.8% |
| Revenue (ttm) | 8.27B +2.9% |
| Net Income | 2.32B +7.4% |
| EPS | 5.30 +11.0% |
| Shares Out | n/a |
| PE Ratio | 11.87 |
| Forward PE | 10.92 |
| Dividend | 1.77 (2.68%) |
| Ex-Dividend Date | Apr 20, 2026 |
| Volume | n/a |
| Open | 65.30 |
| Previous Close | 65.48 |
| Day's Range | 65.30 - 66.18 |
| 52-Week Range | 63.48 - 150.12 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Zoetis
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and ... [Read more]
Financial Performance
In 2025, Zoetis's revenue was $9.47 billion, an increase of 2.28% compared to the previous year's $9.26 billion. Earnings were $2.67 billion, an increase of 7.52%.
Financial numbers in USD Financial StatementsNews
Zoetis Transcript: 46th Annual William Blair Growth Stock Conference
The business continues to prioritize innovation and global expansion, with a robust pipeline targeting key unmet needs in animal health. Despite macro headwinds and increased competition, long-term secular trends and a diversified portfolio support growth. Shareholder returns remain a focus, with significant free cash flow enabling ongoing dividends and buybacks.
GRABAR LAW OFFICE INVESTIGATES CLAIMS ON BEHALF OF SHAREHOLDERS OF ZOETIS, INC. (ZTS)
Philadelphia, Pennsylvania--(Newsfile Corp. - May 31, 2026) - WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Zoetis, Inc. (NYSE: ZTS).
ZOETIS INC. (ZTS) INVESTOR ALERT Investors With Large Losses in Zoetis Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquire...
Zoetis Transcript: Stifel Jaws & Paws Conference 2026
Guidance for 2026 anticipates 2%-5% organic growth, driven by improvements in OA pain, livestock, and diagnostics, while competitive and macro headwinds persist. No major price resets are planned; focus remains on innovation, targeted promotions, and loyalty programs. New product launches and pipeline investments are expected to support long-term growth.
Zoetis downgraded to Hold from Buy at Argus
Argus analyst Jasper Hellweg downgraded Zoetis (ZTS) to Hold from Buy.
Zoetis cut to Hold at Argus amid deteriorating investor confidence
As previously reported, Argus downgraded Zoetis (ZTS) to Hold from Buy. The firm cites the company’s stock price experiencing a dramatic decline of 22% in a single-day and further losses…
Zoetis put volume heavy and directionally bearish
Bearish flow noted in Zoetis (ZTS) with 4,490 puts trading, or 1.4x expected. Most active are Jun-26 85 calls and Jul-26 65 puts, with total volume in those strikes near…
Zoetis price target lowered to $95 from $105 at Stifel
Stifel lowered the firm’s price target on Zoetis (ZTS) to $95 from $105 and keeps a Hold rating on the shares. Zoetis’ revised 2026 guidance implies things improve, yet near-term…
Zoetis to Participate in Upcoming Investor Conferences
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that a representative of the company will participate in fireside chats at the following investor confe...
Zoetis Declares Third Quarter 2026 Dividend
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the third quarter of 2026. The dividend will b...
Zoetis Transcript: AGM 2026
The meeting covered board elections, executive compensation, and a shareholder proposal on written consent. Financial results showed solid growth despite competitive pressures, with strategic focus on innovation, AI, and portfolio expansion. Recovery is expected in the second half of 2026.
Michael Burry just loaded up on these 5 'beaten-down' stocks
Big Short investor Michael Burry is aggressively reallocating capital toward beaten-down stocks, warning the artificial intelligence (AI) boom increasingly resembles the dot-com era. According to him,...
Zoetis price target lowered to $112 from $145 at Citi
Citi lowered the firm’s price target on Zoetis (ZTS) to $112 from $145 and keeps a Buy rating on the shares. The firm cut the company’s estimates following the “difficult”…
Zoetis price target lowered to $115 from $160 at Morgan Stanley
Morgan Stanley analyst Erin Wright lowered the firm’s price target on Zoetis (ZTS) to $115 from $160 and keeps an Overweight rating on the shares.
Zoetis price target lowered to $99 from $130 at UBS
UBS lowered the firm’s price target on Zoetis (ZTS) to $99 from $130 and keeps a Neutral rating on the shares.
Zoetis price target lowered to $105 from $130 at Stifel
Stifel lowered the firm’s price target on Zoetis (ZTS) to $105 from $130 and keeps a Hold rating on the shares.
Zoetis price target lowered to $130 from $190 at JPMorgan
JPMorgan lowered the firm’s price target on Zoetis (ZTS) to $130 from $190 and keeps an Overweight rating on the shares.
Morning Movers: Planet Fitness and Zoetis sink after quarterly results
Futures are higher this morning, helped by another sharp decline in oil prices on optimism around a potential U.S.-Iran framework agreement. Crude dropping back toward the low-$90s is relieving pressu...
Zoetis Q1 ‘worse than it seems,’ says Stifel
Stifel notes that Zoetis (ZTS) Q1 organic operational revenue growth was flat versus the firm’s forecast for 2.4% growth and the Street’s 2.2% expectation. However, Zoetis’ results benefited from a…
Zoetis Is Today's Worst S&P 500 Stock. Here's Why.
The animal-health company missed first-quarter earnings estimates.
Zoetis Earnings Call Transcript: Q1 2026
Q1 2026 saw flat organic revenue and 1% adjusted net income growth, with strong international and livestock performance offsetting U.S. and companion animal declines. Guidance for 2026 expects 2%-5% organic revenue growth amid ongoing macro and competitive headwinds.
Zoetis Earnings release: Q1 2026
Zoetis released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Zoetis Slides: Q1 2026
Zoetis has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Zoetis Quarterly report: Q1 2026
Zoetis has published its Q1 2026 quarterly earnings report on May 7, 2026.